Zomedica Corp. (AMEX:ZOM) does about 9.71M shares in volume on a normal day but saw 16736301 shares change hands in Monday trading. The company now has a market cap of 267.69M USD. Its current market price is $0.27, marking a decrease of -3.05% compared to the previous close of $0.28. The 52 week high reached by this stock is $0.50 whilst the lowest price level in 52 weeks is $0.15. The script in recent trading has seen the stock touch a high of $0.28 and a low of $0.27.
Zomedica Corp. (ZOM) has a 20-day trading average at $0.2179 and the current price is -45.90% off the 52-week high compared with 80.33% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.2088 and its 200-day simple moving average is $0.2401. If we look at the stock’s price movements over the week, volatility stands at 15.82%, which decreases to 10.43% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 65.60 to suggest the stock is neutral.
1 analysts observing the Zomedica Corp. (ZOM) stock have set the 12-month price targets for the company’s shares at between $6.00 and $6.00. The consensus objective for the share price is $6.00, suggesting that the stock has a potential upside of 95.5% over the period. The median price target is 95.5% away from the current levels at $6.00.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on January 06, 2023 when Dawson James initiated the stock to “Buy” and issued a price target of $6.
The current price level is 27.18%, 30.02%, and 12.54% away from its SMA20, SMA50, and SMA200 respectively, with the ZOM price moving below the 50-day SMA on January 23. Zomedica Corp. (ZOM) stock is up 8.24% over the week and 62.85% over the past month. Its price is 65.95% year-to-date and -17.78% over the past year.
The stock last released its quarterly earnings report for quarter ended 12/30/2020, with the company’s earnings per share (EPS) of -$0.01 below consensus estimates by -$0.01. The company’s next earnings report is expected on 05/11/2023. Expected sales for next quarter are $1.1 million, which analysts say will come at $4.43 million for the current fiscal year and next year at $15.21 million.
Its 12-month price target is $6.00. To reach the target analysts have set, the stock logically needs to grow 95.5 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $6.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $6.00.
Outstanding shares total 979.95M with insiders holding 1.48% of the shares and institutional holders owning 9.89% of the company’s common stock. The company has a return on investment of -6.80% and return on equity of -6.50%. The beta has a value of 0.82. Price to book ratio is 1.00 and price to sales ratio is 15.84.
Vanguard Total Stock Market Index isn’t the only investment manager who changed stakes and is followed by Vanguard Extended Market Index Fu, which added 21318.0 shares to end up with 13,497,669 shares worth $2.2 million.